Yihan Liu, Haojie Xue, Yang Liu, Han Li, Qian Liang, Longhui Ma, Ming Zhao, Junying Liu
{"title":"Serum insulin-like growth factor 1 and the prognosis of patients with advanced liver diseases: a meta-analysis.","authors":"Yihan Liu, Haojie Xue, Yang Liu, Han Li, Qian Liang, Longhui Ma, Ming Zhao, Junying Liu","doi":"10.14309/ctg.0000000000000829","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Serum insulin-like growth factor 1 (IGF-1), a hepatocyte-derived cytokine, has been suggested to reflect hepatic function reserve. The aim of this systematic review and meta-analysis was to investigate the association between serum IGF-1 levels upon the admission and prognosis of patients with advanced liver diseases.</p><p><strong>Methods: </strong>A thorough examination of the literature was conducted across various databases, namely PubMed, Embase, Web of Science, Wanfang, and CNKI, with the aim of identifying relevant cohort studies. The data were synthesized using the random-effects model, taking into account the potential impact of heterogeneity.</p><p><strong>Results: </strong>A total of nine cohorts were included. Patients with a low serum level of IGF-1, as compared to those with a high IGF-1 at baseline, exhibited a significantly poorer transplant-free survival (risk ratio [RR]: 3.03, 95% confidence interval: 2.17 to 4.22, p < 0.001), with no significant heterogeneity observed (p for Cochrane Q test = 0.92, I2 = 0%). A sensitivity analysis, which was conducted by excluding one study at a time, yielded consistent results (RR: 2.94 to 3.24, p all < 0.05). Additionally, consistent results were observed in further subgroup analyses based on various factors, including cutoffs of IGF-1, country of the study, patient diagnosis, methods for measuring serum IGF-1, follow-up duration, analytic model, and quality scores (p for subgroup difference all > 0.05).</p><p><strong>Conclusions: </strong>A diminished serum IGF-1 level upon admission could potentially serve as an indicator for an unfavorable prognosis among patients afflicted with advanced liver disease, such as severe hepatitis and cirrhosis.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000829","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Serum insulin-like growth factor 1 (IGF-1), a hepatocyte-derived cytokine, has been suggested to reflect hepatic function reserve. The aim of this systematic review and meta-analysis was to investigate the association between serum IGF-1 levels upon the admission and prognosis of patients with advanced liver diseases.
Methods: A thorough examination of the literature was conducted across various databases, namely PubMed, Embase, Web of Science, Wanfang, and CNKI, with the aim of identifying relevant cohort studies. The data were synthesized using the random-effects model, taking into account the potential impact of heterogeneity.
Results: A total of nine cohorts were included. Patients with a low serum level of IGF-1, as compared to those with a high IGF-1 at baseline, exhibited a significantly poorer transplant-free survival (risk ratio [RR]: 3.03, 95% confidence interval: 2.17 to 4.22, p < 0.001), with no significant heterogeneity observed (p for Cochrane Q test = 0.92, I2 = 0%). A sensitivity analysis, which was conducted by excluding one study at a time, yielded consistent results (RR: 2.94 to 3.24, p all < 0.05). Additionally, consistent results were observed in further subgroup analyses based on various factors, including cutoffs of IGF-1, country of the study, patient diagnosis, methods for measuring serum IGF-1, follow-up duration, analytic model, and quality scores (p for subgroup difference all > 0.05).
Conclusions: A diminished serum IGF-1 level upon admission could potentially serve as an indicator for an unfavorable prognosis among patients afflicted with advanced liver disease, such as severe hepatitis and cirrhosis.
期刊介绍：
Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease.
Colon and small bowel
Endoscopy and novel diagnostics
Esophagus
Functional GI disorders
Immunology of the GI tract
Microbiology of the GI tract
Inflammatory bowel disease
Pancreas and biliary tract
Liver
Pathology
Pediatrics
Preventative medicine
Nutrition/obesity
Stomach.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
